Rice Hall James & Associates
Rice Hall James & Associates reported 237 stocks worth $1.9B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LGND (3.7%), ACIW (2.5%) and ARLO (2.4%). Compared with Q2 2026, the fund opened new positions in BFAM and STUB, added to FOUR, PBH and WIX, trimmed LGND, ACIW and ARLO and sold out of VREX, LNTH and CEVA.
Latest filing: what Rice Hall James & Associates did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() LGND Ligand Pharmaceuticals Inc | $69.9M | 3.7% | 224K | −46K (−17%) | 8 of 8 | |
| 2 | ![]() ACIW Aci Worldwide Inc | $47.7M | 2.5% | 977K | −30K (−3%) | 8 of 8 | |
| 3 | ![]() ARLO Arlo Technologies Inc | $45.3M | 2.4% | 3.7M | −78K (−2%) | 8 of 8 | |
| 4 | ![]() ZD Ziff Davis Inc | $45.1M | 2.4% | 795K | −27K (−3%) | 8 of 8 | |
| 5 | ![]() XPO Xpo Inc | $38.6M | 2.0% | 219K | −5,463 (−2%) | 8 of 8 | |
| 6 | ![]() FN Fabrinet | $36.3M | 1.9% | 86K | −1,978 (−2%) | 8 of 8 | |
| 7 | ![]() FOUR SHIFT4 Pmts Inc | $35.2M | 1.9% | 973K | +99K (+11%) | 8 of 8 | |
| 8 | ![]() DFIN Donnelley Finl Solutions Inc | $34.9M | 1.9% | 739K | −36K (−5%) | 8 of 8 | |
| 9 | ![]() PBH Prestige Consmr Healthcare I | $34.8M | 1.9% | 759K | +70K (+10%) | 8 of 8 | |
| 10 | ![]() KNSA Kiniksa Pharmaceuticals Intl | $34.8M | 1.8% | 466K | −159K (−25%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() VREX Varex Imaging Corp | $15.1M | 1.4M |
CHART INDS INC | $7.9M | 38K |
CRINETICS PHARMACEUTICALS IN | $7.3M | 196K |
![]() LNTH Lantheus Hldgs Inc | $4.9M | 44K |
![]() CEVA Ceva Inc | $4.6M | 98K |
🔒 Free account: see all 13.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Rice Hall James & Associates 13F FAQ
What does Rice Hall James & Associates own?
Rice Hall James & Associates reported 237 stocks worth $1.9B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LGND (3.7%), ACIW (2.5%) and ARLO (2.4%). The table above lists every position in the filing (the top 10 without an account).
What did Rice Hall James & Associates buy and sell in Q3 2026?
Compared with Q2 2026: 10 new positions, 38 added to, 174 trimmed and 13 sold out. New positions include BFAM and STUB. It sold all of VREX, LNTH and CEVA.
When will Rice Hall James & Associates file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Rice Hall James & Associates's portfolio worth?
The Q3 2026 filing reports $1.9B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.






















